Core Viewpoint - SciSparc Ltd. experienced a significant stock price increase of 89.13% to $3.48 in after-hours trading following a court-granted stay in merger proceedings with AutoMax Motors Ltd. [1] Group 1: Merger Proceedings - The Jerusalem District Court has granted AutoMax's request to delay merger proceedings until September 30 due to concerns about completing the merger and meeting closing conditions [2] - A merger agreement was signed between SciSparc and AutoMax on April 10, 2024, which has been revised due to operational difficulties at AutoMax [3] Group 2: Stock Performance - In 2025, SciSparc's stock saw a significant decline of 75.66%, with a high of $22.47 on January 6 and a low of $1.80 by Monday, with trading volume dropping to 123,000 shares [4] - The market capitalization of SciSparc is $2.98 million, with the stock trading between $1.75 and $37.59 over the past year, and it remains down 71.87% despite the recent surge [5] - During the regular trading session on Tuesday, the stock experienced a 2.22% increase [5]

As filed with the Securities and Exchange Commission on August 19, 2025 Registration No. 333-289293 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 Amendment No. 1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 N2OFF, INC. (Exact name of registrant as specified in its charter) (State or jurisdiction of (Primary Standard Industrial (I.R.S. Employer incorporation or organization) Classification Code Number) Identification Number) Nevada 2000 26-4684680 HaPardes 134 (M ...

As filed with the Securities and Exchange Commission on August 19, 2025 Registration No. 333-289293 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 Amendment No. 1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 N2OFF, INC. (Exact name of registrant as specified in its charter) (State or jurisdiction of (Primary Standard Industrial (I.R.S. Employer incorporation or organization) Classification Code Number) Identification Number) Nevada 2000 26-4684680 HaPardes 134 (M ...

Core Viewpoint - Clearmind Medicine Inc. has announced the publication of an international patent application for a combination therapy aimed at treating metabolic syndrome and obesity, in collaboration with SciSparc Ltd. [1][2] Group 1: Patent and Collaboration - The patent application covers a combination therapy of Clearmind's proprietary 5-methoxy-2-aminoindane (MEAI) and SciSparc's Palmitoylethanolamide (PEA) [2] - This collaboration has resulted in the filing of 13 patent families across multiple jurisdictions, including the United States, Europe, and China [4] - The focus of the collaboration is on developing therapies that combine neuroplastogens with N-acylethanolamines to address various health disorders [4] Group 2: Health Impact and Market Potential - Metabolic syndrome affects up to one-third of U.S. adults, increasing the risk of serious health issues such as heart disease and type 2 diabetes [3] - The proprietary combination therapy aims to leverage MEAI's pharmacological profile and PEA's anti-inflammatory properties to provide a safe and effective treatment for these health challenges [3] Group 3: Company Strategy and Intellectual Property - The company is committed to developing breakthrough therapies for complex health conditions, with a focus on metabolic syndrome and obesity [5] - Clearmind's intellectual property portfolio currently consists of 19 patent families, including 31 granted patents, with plans to seek additional patents as warranted [6]

As filed with the Securities and Exchange Commission on August 6, 2025 Registration No. 333-______ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 N2OFF, INC. (Exact name of registrant as specified in its charter) incorporation or organization) Classification Code Number) Identification Number) Nevada 2000 26-4684680 (State or jurisdiction of (Primary Standard Industrial (I.R.S. Employer HaPardes 134 (Meshek Sander) Nev ...

Core Viewpoint - Clearmind Medicine Inc. has filed a new international patent application for a combination therapy aimed at addressing obesity and metabolic dysfunction-associated steatotic liver disease (MASLD) [1][2][3] Company Overview - Clearmind is a clinical-stage biotech company focused on developing psychedelic-derived therapeutics to tackle significant health issues, including alcohol use disorder [4] - The company currently holds a portfolio of nineteen patent families, which includes 31 granted patents, and plans to seek additional patents as necessary [5] Health Challenges Addressed - The proprietary combination therapy targets obesity, which affects over 890 million people globally, and MASLD, impacting more than 30% of the adult population [2] - The treatment options for these conditions remain limited despite their widespread prevalence [2] Therapeutic Approach - The combination therapy utilizes MEAI (5-methoxy-2-aminoindane) and Palmitoylethanolamide (PEA), leveraging MEAI's pharmacological profile and PEA's anti-inflammatory and neuroprotective properties [3] - The company believes this novel approach could provide a safe and effective therapeutic alternative for patients [3] Collaboration - The patent filing is part of an ongoing collaboration with SciSparc Ltd., which is also focused on developing therapies for central nervous system disorders [3]

Core Insights - Clearmind Medicine Inc. has announced the publication of a European patent application, strengthening its global intellectual property position and focusing on addiction treatment [1][2] Intellectual Property - The patent EP 4531826 covers Clearmind's proprietary psychedelic-based combination therapy, which includes MEAI and certain N-Acylethanolamines for treating cocaine addiction [2] - The company's intellectual portfolio consists of nineteen patent families, including 31 granted patents, with plans to seek additional patents as warranted [7] Research and Development - Preclinical trials led by Professor Gal Yadid at Bar-Ilan University demonstrated that MEAI significantly reduced cocaine-induced cravings in animals [3] - Further studies showed that MEAI reduced cocaine-seeking behavior without impairing responses to natural rewards, indicating a targeted effect on drug-related compulsions [4] Strategic Collaboration - The patent application is part of an ongoing collaboration with SciSparc Ltd. to explore the combined potential of MEAI and PEA-based technologies for treating central nervous system disorders [5] Company Overview - Clearmind is a clinical-stage biotech company focused on developing psychedelic-derived therapeutics for under-treated health problems, including substance use disorders [6]